PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

• Published in: Journal of nanobiotechnology 2024-07, Vol.22 (1), p.442-20, Article 442
• Main Authors: Du, Li, Gong, Yao, Zhang, Xiaoying, Sun, Jide, Gao, Fengxia, Shen, Meiying, Bai, Huili, Yang, Tiantian, Cheng, Xiaoxue, Li, Siqiao, Peng, Jian, Liu, Zhangling, Ding, Shijia, Chen, Junman, Cheng, Wei
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Anti-tumor immune response; B7-H1 Antigen - metabolism; Cancer; Care and treatment; Cell Line, Tumor; Chemotherapy; Diagnosis; Elastase; Female; Gene Silencing; Humans; Immune response; Immunotherapy; Immunotherapy - methods; Liposomes; Liposomes - chemistry; Metastasis; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles - chemistry; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - therapy; Patient outcomes; PD-L1 siRNA; Polyethyleneimine; Polyethyleneimine - chemistry; Proteases; RNA, Small Interfering - chemistry; Testing; Tumor antigens
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-024-02700-4

PD-1/PD-L1 blockade has become a powerful method to treat malignant tumors. However, a large proportion of patients still do not benefit from this treatment, due to low tumor immunogenicity and low tumor penetration of the agents. Recently, neutrophil elastase has been shown to induce robust tumor immunogenicity, while the insufficient enzyme activity at the tumor site restricted its anti-tumor application. Here, we designed polyethyleneimine-modified neutrophil elastase (PEI-elastase) loaded with PD-L1small interfering RNA (PD-L1 siRNA) for improving enzymatic activity and delivering siRNA to tumor, which was expected to solve the above-mentioned problems. We first demonstrated that PEI-elastase possessed high enzymatic activity, which was also identified as an excellent gene-delivery material. Then, we synthesized anti-tumor lipopolymer (P-E/S Lip) by encapsulating PEI-elastase and PD-L1siRNA with pH-responsive anionic liposomes. The P-E/S Lip could be rapidly cleaved in tumor acidic environment, leading to exposure of the PEI-elastase/PD-L1 siRNA. Consequently, PEI-elastase induced powerful tumor immunogenicity upon direct tumor killing with minimal toxicity to normal cells. In parallel, PEI-elastase delivered PD-L1siRNA into the tumor and reduced PD-L1 expression. Orthotopic tumor administration of P-E/S Lip not only attenuated primary tumor growth, but also produced systemic anti-tumor immune response to inhibit growth of distant tumors and metastasis. Moreover, intravenous administration of P-E/S Lip into mice bearing subcutaneous tumors leaded to an effective inhibition of established B16-F10 tumor and 4T1 tumor, with histological analyses indicating an absence of detectable toxicity. In our study, a protease-based nanoplatform was used to cooperatively provoke robust tumor immunogenicity and down-regulate PD-L1 expression, which exhibited great potential as a combination therapy for precisely treating solid tumors.